BDTX — Black Diamond Therapeutics Share News
0.000.00%
Last trade - 00:00- $100.28m
- -$17.98m
- $70.00m
Black Diamond Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
Black Diamond Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Black Diamond Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Black Diamond Therapeutics Announces Restructuring Plan To Focus Resources On Bdtx-1535 And Extend Cash Runway
U.S. RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks
U.S. RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks
Europe Research Roundup: Costco Wholesale, McKesson, Starbucks
Black Diamond Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Black Diamond Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview
Black Diamond Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Black Diamond Therapeutics Announces Changes To Board
U.S. RESEARCH ROUNDUP- Biomea Fusion, BlackRock, Capital Bancorp
Black Diamond Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Black Diamond Therapeutics Announces Corporate Update And Expected 2024 Milestones
Brief: Black Diamond Therapeutics Says BDTX-1535 Generally Well Tolerated, Consistent With Prior Disclosures And No New Safety Signals Observed
Brief: Black Diamond Therapeutics Q3 basic EPS USD -0.45
Black Diamond Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses In Patients With Nsclc From Phase 1 Trial Of Bdtx-1535
U.S. STOCKS ON THE MOVE-Knowles, RE/MAX Holdings, BioCryst Pharma